Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavapadon - Cerevel Therapeutics

Next Previous
Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: CVL 751; PF 6649751; PF-06649751

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 08 Sep 2025 AbbVie initiates an expanded-access programme for Parkinson disease in USA (PO) (NCT07158827)
  • 16 Jun 2025 AbbVie completes a phase I relative bioavailability trial (In volunteers) in USA (PO, Tablet) (NCT06895356)
  • 05 Apr 2025 Updated efficacy from a phase III trial in Parkinson's disease presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top